Graig Suvannavejh
Stock Analyst at Mizuho
(4.40)
# 354
Out of 5,140 analysts
170
Total ratings
56.25%
Success rate
17.04%
Average return
Main Sectors:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Outperform | $205 | $93.92 | +118.27% | 1 | Jan 7, 2026 | |
| ERAS Erasca | Maintains: Outperform | $4 → $5 | $10.05 | -50.25% | 1 | Dec 9, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $33 → $54 | $36.66 | +47.30% | 9 | Dec 9, 2025 | |
| BLTE Belite Bio | Upgrades: Outperform | $105 → $194 | $159.19 | +21.87% | 2 | Dec 2, 2025 | |
| INSM Insmed | Maintains: Outperform | $196 → $256 | $156.32 | +63.77% | 12 | Dec 1, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $39 → $46 | $36.69 | +25.37% | 21 | Dec 1, 2025 | |
| TARS Tarsus Pharmaceuticals | Initiates: Outperform | $100 | $71.25 | +40.35% | 1 | Nov 20, 2025 | |
| IMTX Immatics | Maintains: Outperform | $19 → $23 | $9.98 | +130.46% | 4 | Nov 19, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $54 → $56 | $71.71 | -21.91% | 7 | Nov 18, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $44 → $46 | $36.01 | +27.74% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $202 | $189.10 | +6.82% | 22 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $19 | $20.95 | -9.31% | 11 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2 → $4 | $1.84 | +117.39% | 9 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $0.60 | +4,878.43% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2.5 → $3.5 | $1.92 | +82.29% | 5 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $1.95 | +156.41% | 2 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $4.85 | +106.19% | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $11 | $22.15 | -50.34% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $15.53 | +67.42% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $16.92 | -52.72% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $35.25 | -6.38% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.47 | +417.01% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $8.66 | +754.50% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $3.14 | -68.15% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $106.02 | -66.99% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $26.71 | -70.05% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $63.04 | -9.58% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $31.57 | -84.16% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $9.92 | +242.74% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $9.55 | +193.19% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $29.24 | +6.02% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $380 | $18.08 | +2,001.77% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.81 | +162.43% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $26.70 | +34.83% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $33.49 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $1.82 | +1,932.97% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $169.16 | -24.33% | 1 | Sep 14, 2020 |
Palvella Therapeutics
Jan 7, 2026
Initiates: Outperform
Price Target: $205
Current: $93.92
Upside: +118.27%
Erasca
Dec 9, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $10.05
Upside: -50.25%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $33 → $54
Current: $36.66
Upside: +47.30%
Belite Bio
Dec 2, 2025
Upgrades: Outperform
Price Target: $105 → $194
Current: $159.19
Upside: +21.87%
Insmed
Dec 1, 2025
Maintains: Outperform
Price Target: $196 → $256
Current: $156.32
Upside: +63.77%
Harmony Biosciences Holdings
Dec 1, 2025
Maintains: Outperform
Price Target: $39 → $46
Current: $36.69
Upside: +25.37%
Tarsus Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $100
Current: $71.25
Upside: +40.35%
Immatics
Nov 19, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $9.98
Upside: +130.46%
Halozyme Therapeutics
Nov 18, 2025
Maintains: Neutral
Price Target: $54 → $56
Current: $71.71
Upside: -21.91%
IDEAYA Biosciences
Nov 11, 2025
Maintains: Outperform
Price Target: $44 → $46
Current: $36.01
Upside: +27.74%
Nov 6, 2025
Maintains: Outperform
Price Target: $200 → $202
Current: $189.10
Upside: +6.82%
Nov 3, 2025
Maintains: Neutral
Price Target: $24 → $19
Current: $20.95
Upside: -9.31%
Sep 12, 2025
Maintains: Neutral
Price Target: $2 → $4
Current: $1.84
Upside: +117.39%
Sep 8, 2025
Initiates: Outperform
Price Target: $30
Current: $0.60
Upside: +4,878.43%
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $1.92
Upside: +82.29%
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $1.95
Upside: +156.41%
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $4.85
Upside: +106.19%
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $22.15
Upside: -50.34%
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $15.53
Upside: +67.42%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $16.92
Upside: -52.72%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $35.25
Upside: -6.38%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.47
Upside: +417.01%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $8.66
Upside: +754.50%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $3.14
Upside: -68.15%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $106.02
Upside: -66.99%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $26.71
Upside: -70.05%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $63.04
Upside: -9.58%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $31.57
Upside: -84.16%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $9.92
Upside: +242.74%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $9.55
Upside: +193.19%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $29.24
Upside: +6.02%
Mar 2, 2021
Initiates: Sell
Price Target: $380
Current: $18.08
Upside: +2,001.77%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.81
Upside: +162.43%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $26.70
Upside: +34.83%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $33.49
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $1.82
Upside: +1,932.97%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $169.16
Upside: -24.33%